Centocor sells UK plant to Trinity Biotech
This article was originally published in Clinica
Centocor, the US biotech company, has sold its UK diagnostic test factory to Trinity Biotech for $5.5 million. The plant, in Guildford, Surrey, develops and manufactures infectious disease tests in microtitre EIA (enzyme immunoassay) plate format. These include tests for rubella, herpes, syphilis and a recently developed test for Chagas disease. The business had a turnover of $3.2 million in 1996.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.